Veracyte Inc (VCYT) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Total Revenue Chart for Veracyte Inc
Veracyte Inc (VCYT) revenue for FY2025 was USD 517.1M, a 16.0% change from FY2024. Veracyte Inc's revenue grew from USD 2.6M in 2011 to USD 517.1M in 2025 (19451.8% over 14 years). Earnings per share moved from USD -6.15 in 2013 to USD -0.51 in 2022. Revenue compound annual growth rate: 5-year CAGR of 34.5%, 10-year CAGR of 26.4%.
Total Revenue (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $3.47B
- Implied Share Price
- $43.12
- Enterprise Value
- $3.08B
- Revenue (TTM)
- $561.90M
- EBITDA
- $113.52M
- Profit Margin
- 20.37%
- Trailing P/E
- 30.80
- Forward P/E
- 23.58
- Price/Book (MRQ)
- 2.54
- Price/Sales (TTM)
- 6.17
- EV/EBITDA
- 22.51
- EV/Revenue
- 5.48
- Dividend Yield
- —
- Book Value
- $17.28
- Free Cash Flow (FY2025)
- $126.63M
- Free Cash Flow Yield
- 3.65%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.